Anthracycline‐induced cardiomyopathy: secrets and lies
- 1 March 2018
- journal article
- editorial
- Published by Wiley in European Journal of Heart Failure
- Vol. 20 (5), 907-909
- https://doi.org/10.1002/ejhf.1172
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesEuropean Journal of Heart Failure, 2016
- Cardio-OncologyCirculation Research, 2016
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure TherapyCirculation, 2015
- Prevention of Anthracycline-Induced CardiotoxicityJournal of the American College of Cardiology, 2014
- Insights Into Onco-CardiologyJournal of the American College of Cardiology, 2014
- Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for CareCancer Epidemiology, Biomarkers & Prevention, 2013
- Cancer drugs and the heart: importance and managementEuropean Heart Journal, 2012
- Abstract LB-339: Cause of death in cancer survivorsCancer Research, 2012
- Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic TherapyJournal of the American College of Cardiology, 2010
- Congestive heart failure in patients treated with doxorubicinCancer, 2003